Salute e Benessere

LIAN Group Expands Healthcare Platform with Strategic Acquisition of Scientis…

"We are thrilled to welcome Scientis to LIAN Group's healthcare platform. We are committed to accelerating Scientis' growth and sales in new markets by leveraging our network, expertise and resources to expand into new markets, streamline operations, develop innovative products and services, and empower patients and healthcare professionals with high-quality solutions." says Fiorenzo Manganiello, Managing Partner of LIAN Group. "We are thrilled to welcome Scientis to LIAN Group's…
PR Newswire
27/08/2024

Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT

HHT, an Orphan Disease, is the second most common inherited bleeding disorder in the world frequently causing severe disease burden, reduced life expectancy and impaired Quality of Life. Despite this, there remains no approved treatment for HHT anywhere in the world. Vaderis is developing VAD044, an oral, once-daily allosteric AKT-inhibitor, the first novel therapy intended specifically for the treatment of HHT. In this controlled, double-blind trial, seventy-five patients across...
PR Newswire
27/08/2024

From Care to Connection: KFSHRC Champions Community Engagement

RIYADH, Saudi Arabia, Aug.27, 2024(GLOBE NEWSWIRE) -- In alignment with Saudi Arabia's Vision 2030 healthcare goals, King Faisal Specialist Hospital & Research Centre (KFSHRC) leads in healthcare innovation with pioneering programs that train future leaders and positively impact the Saudi community. KFSHRC's Education and Training department ensures the institution's educational programs maintain high standards across all residency and fellowship programs. Recent accreditations...
Nasdaq GlobeNewswire
27/08/2024

Study results from phase 1 studies with exidavnemab published in The Journal of…

The results showed that exidavnemab was generally well-tolerated. with an excellent half-life of approximately 30 days. This together with the high affinity and selectivity toward the pathological aggregated forms of α-synuclein is key to maintain a high target binding in the brain. The results showed that exidavnemab was generally well-tolerated. with an excellent half-life of approximately 30 days. This together with the high affinity and selectivity toward the pathological aggregated forms...
PR Newswire
27/08/2024

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore

COPENHAGEN, Denmark, August 27, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today that Singapore's medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS ®(MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.This marks the transition to a full approval for JYNNEOS in Singapore, where like in many other countries, the vaccine was made available under...
Nasdaq GlobeNewswire
27/08/2024

Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate Potravitug entering Phase III trial Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG(or “MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces that Alex Bastian...
Nasdaq GlobeNewswire
27/08/2024

HKBU research identifies potential of phosphocholine in counteracting PM2.5…

PM2.5 increases health risks PM2.5 increases health risks The World Health Organisation has linked air pollution to an estimated seven million deaths annually, and recognising it as the leading environmental risk factor globally. PM2.5, a major air pollutant, increases the risk of health problems such as heart and lung diseases. Every type of PM2.5 component possesses distinct impacts on human health. However, the understanding of the toxicity effects of individual PM2.5 components remains...
PR Newswire
27/08/2024

European Commission Decision to approve the pediatric use of antifungal…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the European Commission (EC) has extended the indications of the antifungal Cresemba ®(isavuconazole) to pediatric patients and also granted an extension of market exclusivity by two additional years,...
Nasdaq GlobeNewswire
27/08/2024

Probiotic Skin Care Cosmetic Product Market to Reach $981.3 Million, Globally…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06317 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A06317 Prime determinants of growth Increase in consumer awareness about the benefits of probiotics for skin health has fueled demand, as probiotics are known to balance the skin microbiome, reduce inflammation, and enhance skin barrier function. Growing interest in natural and organic...
PR Newswire
27/08/2024

Bone Harvester Market to Reach $23.4 Million, Globally, by 2033 at 5.7% CAGR…

The global bone harvester market is experiencing growth due to surge in geriatric population, high adoption of bone marrow transplantation, and rise in prevalence of orthopedic disorders. Furthermore, the developing healthcare infrastructure in the developing nations such as India, China, and Middle Eastern countries is expected to provide significant opportunity for growth. The global bone harvester market is experiencing growth due to surge in geriatric population, high adoption of bone...
PR Newswire
27/08/2024

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior has selected a compound for future...
Nasdaq GlobeNewswire
27/08/2024

Roche's PiaSky approved in the EU as the first monthly subcutaneous treatment…

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval is based on COMMODORE 2, where subcutaneous (SC) PiaSky once a month was equivalent to intravenous eculizumab every two weeks 1,2 PiaSky advances C5 inhibitionthrough innovative recycling technology, which enables its monthly SC administration 3Basel, 27 August 2024 - Roche...
Nasdaq GlobeNewswire
27/08/2024

IBA secures deal with the University of Pennsylvania Health System for two…

Agreement further strengthens the long-term relationship between IBA and the University of PennsylvaniaLouvain-La-Neuve, Belgium, August 27, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a Memorandum of Understanding with the University of Pennsylvania Health System for the installation of two Proteus ® ONE 1...
Nasdaq GlobeNewswire
27/08/2024

Kanazawa University research: Atomic force microscopy upgrade captures 3D images…

The hypothesis of a hydration layer forming during the dissolution of calcite was prompted by simulations of the process, which pointed to the production of a Ca(OH)2 layer across 'transition regions' as calcite dissolves. Despite being unstable in the bulk or on flat terraces, Ca(OH)2 can appropriate some stability from step edge structures, although the mechanism behind this is not well understood. This could explain the stability of the Ca(OH)2 next to the step edges but since the transition…
PR Newswire
27/08/2024

Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence…

Avance Clinical comprehensively supports biotech clients through all clinical trial stages—including protocol development, site selection, patient recruitment, and data analysis—and eliminates the need to engage with multiple CROs. This streamlined approach optimizes clinical study efficiencies, minimizes overall costs, and accelerates trial timelines. Moreover, Avance Clinical, as a midsized entity, embeds itself deeply into its biotech customers' operations, with its scientific and regulatory…
PR Newswire
27/08/2024

Telix Announces Reorganisation to Deliver on Strategic Priorities

As part of this initiative, the Company announces three leadership changes: As part of this initiative, the Company announces three leadership changes: Darren Patti remains Group Chief Operating Officer, with leadership responsibility for Telix's internal manufacturing operations, including the operations of ARTMS, IsoTherapeutics and Optimal Tracers, which sit under the TMS umbrella. DrChristian Behrenbruch, Telix Managing Director and Group Chief Executive Officer said the new...
PR Newswire
27/08/2024

Global Wireless Brain Sensors Market to Accelerate Substantially at a CAGR of…

Key Takeaways from the Wireless Brain Sensors Market Report Key Takeaways from the Wireless Brain Sensors Market Report To read more about the latest highlights related to the wireless brain sensors market, get a snapshot of the key highlights entailed in the Global Wireless Brain Sensors Market Report Wireless Brain Sensors Overview Wireless brain sensors are a cutting-edge technology in the field of neuroengineering, designed to monitor brain activity without the need for...
PR Newswire
26/08/2024

Schizophrenia Market: RISVAN's Approval Has Sparked a Competitive Race Among…

Currently, as per the WHO, the vast majority of schizophrenia patients around the world are not receiving mental health care. Approximately 50% of people in mental hospitals have a schizophrenia diagnosis, and only 31.3% of people with psychosis receive specialist mental health care. Currently, as per the WHO, the vast majority of schizophrenia patients around the world are not receiving mental health care. Approximately50%of people in mental hospitals have a schizophrenia diagnosis, and...
PR Newswire
26/08/2024

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

ndAnnual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a...
Nasdaq GlobeNewswire
26/08/2024

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell…

® -mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks. Adoptive cell therapy based on CAR T cells has proven to be lifesaving for many cancer patients. However, its therapeutic efficacy has so far been restricted to only a few malignancies, with solid tumors proving to be especially recalcitrant to efficient therapy.One key factor for this are cancer-associated...
Nasdaq GlobeNewswire
26/08/2024

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq:GMAB) announced today thatits Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 22 ndAnnual Global Healthcare Conference at 1:05PM EDT / 7:05PM CEST on September 4 , 2024. A webcast of the event, which will include brief opening remarks followed by a...
Nasdaq GlobeNewswire
26/08/2024

Ultraviolet Visible Spectroscopy Market worth $1.7 billion by 2029 driven by…

Browse in-depth TOC on "Ultraviolet Visible Spectroscopy Market" Browse in-depth TOC on "Ultraviolet Visible Spectroscopy Market" 223 - Tables 61 - Figures252 - Pages Agilent Technologies, Inc.: Global Provider of Spectroscopy Solutions Agilent Technologies (US) is a leading player in the diagnostics, life sciences, and chemical sectors, offering a range of spectroscopy equipment. The company operates through three primary segments: Life Sciences & Applied Markets,...
PR Newswire
26/08/2024

Injection Pen Market worth $74.1 billion by 2030 driven by Emerging Tech…

Browse in-depth TOC on "Injection Pen Market" Browse in-depth TOC on "Injection Pen Market" 213 - Tables 62 - Figures 242 - Pages Novo Nordisk A/S: Leading Innovator in Injection Pens Novo Nordisk ( Denmark ) emerged as the top player in the global injection pen market in 2023. The company's Diabetes Care segment, which focuses on reusable injection pens, is both its largest and fastest-growing area. Novo Nordisk also provides injection pens for growth hormone treatments...
PR Newswire
26/08/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 26 August 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...
Nasdaq GlobeNewswire
26/08/2024
Altri  Comunicati